Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00955955 · ClinicalTrials.gov registry record · Phase 4
Study of 6(S)-5-MTHF Among Selective Serotonin Reuptake Inhibitor-Resistant Outpatients With Major Depressive Disorder
A Phase 4 study of Depression, sponsored by George I. Papakostas.
- Completed
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
- 6
- Study locations
NCT00955955: Completed Phase 4 study of Depression, sponsored by George I. Papakostas.
NCT00955955 is a Phase 4 study of Depression that has completed, run by George I. Papakostas. The registered enrollment target is 75 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (90% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00955955, a Phase 4 study of Depression, has completed, sponsored by George I. Papakostas.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of the study is to test whether oral 6(S)-5-MTHF (Deplin) is safe and effective in relieving depression when it is added to standard kinds of antidepressants called serotonin reuptake inhibitors (SSRIs).
Conditions Studied
Interventions
- OTHER Placebo
- OTHER 6(S)-5-MTHF(Deplin)
Study Locations (6)
California
- University of California San Diego School of Medicine - San Diego
Illinois
- Rush University Medical Center, Psychiatric Medicine Associates, LLC - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
Ohio
- University of Cincinnati, College of Medicine - Cincinnati
Pennsylvania
- University of Pennsylvania - Philadelphia
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2009-07 |
| Est. Completion | 2011-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00955955
The ClinicalTrials.gov registry entry for NCT00955955 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (90% lower). The listed sponsor is George I. Papakostas, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00955955 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00955955 about?
NCT00955955 is a clinical study titled "Study of 6(S)-5-MTHF Among Selective Serotonin Reuptake Inhibitor-Resistant Outpatients With Major Depressive Disorder". The purpose of the study is to test whether oral 6(S)-5-MTHF (Deplin) is safe and effective in relieving depression when it is added to standard kinds of antidepressants called serotonin reuptake inhibitors (SSRIs).
What is the current status of trial NCT00955955?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2009-07. Estimated completion is 2011-04.
What conditions does trial NCT00955955 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT00955955?
The interventions under investigation include: Placebo (OTHER), 6(S)-5-MTHF(Deplin) (OTHER).
Who is sponsoring clinical trial NCT00955955?
This trial is sponsored by George I. Papakostas, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00955955 being conducted?
This trial has 6 study locations across California, Illinois, Massachusetts, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
-
Dopaminergic Therapy for Anhedonia - 2
RECRUITING · Phase 4
-
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
RECRUITING · Phase 4
-
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
RECRUITING · Phase 4
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
RECRUITING · Phase 4
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.